These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38325244)

  • 21. Budget Impact Analysis of the Change in Peritoneal Dialysis Use Rate in Korea.
    Kim J; Lee NR; Son SK; Lee JP; Park JT; Kim YJ; Ryu DR
    Perit Dial Int; 2019; 39(6):547-552. PubMed ID: 31337696
    [No Abstract]   [Full Text] [Related]  

  • 22. Health economic evaluations: the special case of end-stage renal disease treatment.
    Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
    Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dialysis: Choice of dialysis--what to do with economic incentives.
    Chow KM; Li PK
    Nat Rev Nephrol; 2012 Sep; 8(9):495-6. PubMed ID: 22847345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home Dialysis Utilization Among Racial and Ethnic Minorities in the United States at the National, Regional, and State Level.
    Wallace EL; Lea J; Chaudhary NS; Griffin R; Hammelman E; Cohen J; Sloand JA
    Perit Dial Int; 2017 1-2; 37(1):21-29. PubMed ID: 27680759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Travel distance and home dialysis rates in the United States.
    Prakash S; Coffin R; Schold J; Lewis SA; Gunzler D; Stark S; Howard M; Rodgers D; Einstadter D; Sehgal AR
    Perit Dial Int; 2014; 34(1):24-32. PubMed ID: 24525595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost analysis of dialysis modalities in Italy.
    Tediosi F; Bertolini G; Parazzini F; Mecca G; Garattini L
    Health Serv Manage Res; 2001 Feb; 14(1):9-17. PubMed ID: 11246787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved long-term survival with home hemodialysis compared with institutional hemodialysis and peritoneal dialysis: a matched cohort study.
    Rydell H; Ivarsson K; Almquist M; Segelmark M; Clyne N
    BMC Nephrol; 2019 Feb; 20(1):52. PubMed ID: 30760251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dialysis facility and patient characteristics associated with utilization of home dialysis.
    Walker DR; Inglese GW; Sloand JA; Just PM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1649-54. PubMed ID: 20634324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cost of dialysis in France].
    Benain JP; Faller B; Briat C; Jacquelinet C; Brami M; Aoustin M; Dubois JP; Rieu P; Behaghel C; Duru G
    Nephrol Ther; 2007 Jun; 3(3):96-106. PubMed ID: 17540311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of End-Stage Renal Disease Prospective Payment System on Utilization of Peritoneal Dialysis in Patients with Kidney Allograft Failure.
    Gardezi AI; Yuan Z; Aziz F; Parajuli S; Mandelbrot D; Chan MR; Astor BC
    Am J Nephrol; 2024; 55(5):551-560. PubMed ID: 38754385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Home dialysis gets the spotlight--will it help?
    Neumann ME
    Nephrol News Issues; 2016 Apr; 30(4):8, 10. PubMed ID: 27254896
    [No Abstract]   [Full Text] [Related]  

  • 32. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records.
    Bruns FJ; Seddon P; Saul M; Zeidel ML
    J Am Soc Nephrol; 1998 May; 9(5):884-90. PubMed ID: 9596087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Patient Survival of Home Hemodialysis and Peritoneal Dialysis Patients.
    Choi SJ; Obi Y; Ko GJ; You AS; Eriguchi R; Wang M; Rhee CM; Kalantar-Zadeh K
    Am J Nephrol; 2020; 51(3):192-200. PubMed ID: 31991403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.
    Liu FX; Walton SM; Leipold R; Isbell D; Golper TA
    Perit Dial Int; 2014; 34(7):749-57. PubMed ID: 25292402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of dialysis therapies.
    Klarenbach S; Manns B
    Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making peritoneal dialysis and home hemodialysis more economically viable.
    Sullivan JD
    Nephrol News Issues; 2006 Jul; 20(8):54, 56-8. PubMed ID: 16859233
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemodialysis versus peritoneal dialysis, which is cost-effective?
    Atapour A; Eshaghian A; Taheri D; Dolatkhah S
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):962-5. PubMed ID: 26354569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic differences among patients initiated on home haemodialysis and peritoneal dialysis: the fallacy of potential competition.
    Rioux JP; Bargman JM; Chan CT
    Nephrol Dial Transplant; 2010 Jul; 25(7):2364-7. PubMed ID: 20360014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil.
    de Abreu MM; Walker DR; Sesso RC; Ferraz MB
    Perit Dial Int; 2013; 33(3):304-15. PubMed ID: 23209041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
    De Vecchi AF; Dratwa M; Wiedemann ME
    Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.